Table 3.
Descriptive data of the study population
| Number of participantsa |
Mean ± standard deviation |
|||||
|---|---|---|---|---|---|---|
| overall | women | men | overall | women | men | |
| Age, years | 1,622 | 793 | 829 | 64+5 (range 55-74) | ||
| Waist circumference, cm | 1,622 | 793 | 825 | 96.1 ± 11.8 | 91.0 ± 11.6 | 101.0 ± 9.8 |
| HDL, mmol/1 | 1,620 | 792 | 828 | 1.49 ± 0.42 | 1.63 ± 0.44 | 1.35 ± 0.35 |
| TG, mmol/1 | 1,620 | 785 | 820 | 1.49 ± 1.07 | 1.53 ± 1.00 | 1.76 ± 1.13 |
| Fasting glucose, mg/dl | 1,618 | 791 | 827 | 108 ± 33 | 105 ± 33 | 111 ± 32 |
| Blood pressure, mm Hg | 1,616 | 791 | 825 | 136.5 ± 20.5/80.5 ± 10.6 | 132.3 ± 20.0/78.5 ± 10.1 | 140.5 ± 20.1/82.4 ± 10.6 |
| Number of participants (% of all participants) |
||||||
|---|---|---|---|---|---|---|
| overall | women | men | ||||
| Drug treatmentb | ||||||
| Insulin | 1,617 | 791 | 826 | 33 (2.02%) | 19 (2.40%) | 14 (1.69%) |
| Oral antidiabetics | 1,617 | 791 | 826 | 84 (5.19%) | 33 (4.17%) | 51 (6.17%) |
| Lipid lowering drugs | 1,617 | 791 | 826 | 197 (12.18%) | 89 (11.25%) | 108 (13.08%) |
| Antihypertensives | 1,617 | 791 | 826 | 602 (37.23%) | 302 (38.18%) | 300 (36.32%) |
| Metabolic syndrome (NCEP (AIII)) | 1,604 | 786 | 818 | 659 (41.08%) | 300 (38.17%) | 359 (43.89%) |
a
Number of persons used from KORA S4 study
b
Number of persons with defined drug treatment.